Peter Grauman

8.7k citations

13 papers · 2.7k indexed · 3 hit papers · h-index 9

Impact in

Hematology top 0.5%
- Acute Myeloid Leukemia Research
- Multiple Myeloma Research and Treatments
Genetics top 2%
- Myeloproliferative Neoplasms: Diagnosis and Treatment

Papers in ⓘ

Hematology 8
- Acute Myeloid Leukemia Research 5
- Multiple Myeloma Research and Treatments 3
Molecular Biology 7
- Epigenetics and DNA Methylation 4
- Protein Degradation and Inhibitors 3

Co-authors: Benjamin L. Ebert (9 shared papers)Marie McConkey (4 shared papers)Christie Ciarlo (3 shared papers)Nikhil C. Munshi (1 shared paper)Emily C. Hartman (2 shared papers)Xiaoyu Li (1 shared paper)Monica Schenone (3 shared papers)Stuart L. Schreiber (2 shared papers)
Journals: Blood (6 papers)Clinical Chemistry (1 paper)Science (1 paper)Nature Communications (1 paper)New England Journal of Medicine (1 paper)
Partner nations: United States Germany Netherlands

In The Last Decade

Peter Grauman

12 papers receiving 2.6k citations

Hit Papers

align trajectories log scale

Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation 2017 · 473 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2017 New England Journal of Medicine
2014 Blood
2013 Science

Peers

Countries citing papers authored by Peter Grauman

Since Specialization

Citations

This map shows the geographic impact of Peter Grauman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Grauman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Grauman more than expected).

Fields of papers citing papers by Peter Grauman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Grauman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Grauman. The network helps show where Peter Grauman may publish in the future.

Co-authors

The 25 scholars most cited alongside Peter Grauman, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Peter Grauman Line = papers co-authored together Peter Grauman links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

#	Work
1	Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells Science ·Jan Krönke, Namrata D. Udeshi, Anupama Narla, Peter Grauman, Slater N. Hurst, Marie McConkey, Tanya Svinkina, Dirk Heckl, Eamon Comer, Xiaoyu Li, Christie Ciarlo, Emily C. Hartman, Nikhil C. Munshi, Monica Schenone, Stuart L. Schreiber, Steven A. Carr, Benjamin L. Ebert Hit paper breakdown →	2013	1288
2	Acute myeloid leukemia ontogeny is defined by distinct somatic mutations Blood ·R. Coleman Lindsley, Brenton G. Mar, Emanuele Mazzola, Peter Grauman, Sarah J. Shareef, Steven L. Allen, Arnaud Pigneux, Meir Wetzler, Robert K. Stuart, Harry P. Erba, Lloyd E. Damon, Bayard L. Powell, Neal I. Lindeman, David P. Steensma, Martha Wadleigh, Daniel J. DeAngelo, Donna Neuberg, Richard M. Stone, Benjamin L. Ebert Hit paper breakdown →	2014	595
3	Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation New England Journal of Medicine ·R. Coleman Lindsley, Wael Saber, Brenton G. Mar, Robert Redd, Tao Wang, Michael Haagenson, Peter Grauman, Zhen‐Huan Hu, Stephen R. Spellman, Stephanie J. Lee, Michael R. Verneris, Katharine C. Hsu, Katharina Fleischhauer, Corey Cutler, Joseph H. Antin, Donna Neuberg, Benjamin L. Ebert Hit paper breakdown →	2017	473
4	Mutations in epigenetic regulators including SETD2 are gained during relapse in paediatric acute lymphoblastic leukaemia Nature Communications ·Brenton G. Mar, Lars Bullinger, Kathleen M. McLean, Peter Grauman, Marian H. Harris, Kristen E. Stevenson, Donna Neuberg, Amit Sinha, Stephen E. Sallan, Lewis B. Silverman, Andrew L. Kung, Luca Lo Nigro, Benjamin L. Ebert, Scott A. Armstrong	2014	135
5	SETD2 alterations impair DNA damage recognition and lead to resistance to chemotherapy in leukemia Blood ·Brenton G. Mar, S. Haihua Chu, Josephine Kahn, Andrei V. Krivtsov, Richard P. Koche, Cecilia A. Castellano, Jacob L. Kotlier, Rebecca L. Zon, Marie McConkey, Jonathan Chabon, Ryan Chappell, Peter Grauman, James J. Hsieh, Scott A. Armstrong, Benjamin L. Ebert	2017	88
6	Validation of an Expanded Carrier Screen that Optimizes Sensitivity via Full-Exon Sequencing and Panel-wide Copy Number Variant Identification Clinical Chemistry ·Gregory J. Hogan, Valentina Vysotskaia, Kyle A. Beauchamp, Stefanie Seisenberger, Peter Grauman, Kevin Haas, Sun Hae Hong, Diana Jeon, Shera Kash, H. Henry Lai, Laura M. Melroy, Mark Theilmann, Clement Chu, Kevin Iori, Jared Maguire, Eric A. Evans, Imran S. Haque, Rebecca Mar‐Heyming, Hyunseok P. Kang, Dale Muzzey	2018	46
7	Sequencing as a first-line methodology for cystic fibrosis carrier screening Genetics in Medicine ·Kyle A. Beauchamp, Katherine Johansen Taber, Peter Grauman, Lindsay Spurka, Jeraldine Lim‐Harashima, Ashley Svenson, Judith D. Goldberg, Dale Muzzey	2019	26
8	Development and validation of a 36-gene sequencing assay for hereditary cancer risk assessment PeerJ ·Valentina Vysotskaia, Gregory J. Hogan, Genevieve Gould, Xin Wang, Alex Robertson, Kevin Haas, Mark Theilmann, Lindsay Spurka, Peter Grauman, H. Henry Lai, Diana Jeon, Genevieve Haliburton, Matt Leggett, Clement Chu, Kevin Iori, Jared Maguire, Kaylene Ready, Eric Evans, Hyunseok P. Kang, Imran S. Haque	2017	15
9	Detecting clinically actionable variants in the 3′ exons of PMS2 via a reflex workflow based on equivalent hybrid capture of the gene and its pseudogene BMC Medical Genetics ·Genevieve Gould, Peter Grauman, Mark Theilmann, Lindsay Spurka, Irving E. Wang, Laura M. Melroy, Robert Chin, Dustin Hite, Clement Chu, Jared Maguire, Gregory J. Hogan, Dale Muzzey	2018	14
10	Inhibition of the CRBN-DDB1-CUL4-ROC1 E3 Ubiquitin Ligase Mediates the Anti-Proliferative and Immunomodulatory Properties of Lenalidomide Blood ·Jan Krönke, Anupama Narla, Slater N. Hurst, Namrata D. Udeshi, Monica Schenone, Marie McConkey, Peter Grauman, Dirk Heckl, Randall McAuley, Christie Ciarlo, Eamon Comer, Xiaoyu Li, Steven A. Carr, Benjamin L. Ebert	2012	3
11	Genetic Alterations Predict Outcomes in Patients with Myelodysplastic Syndrome Receiving Allogeneic Hematopoietic Stem Cell Transplantation Blood ·R. Coleman Lindsley, Wael Saber, Brenton G. Mar, Robert Redd, Michael Haagenson, Peter Grauman, Stephen R. Spellman, Stephanie J. Lee, Tao Wang, Michael R. Verneris, Katharine C. Hsu, Katharina Fleischhauer, Corey Cutler, Joseph H. Antin, Donna Neuberg, Benjamin L. Ebert	2016	1
12	Lenalidomide Promotes CRBN-Mediated Ubiquitination and Degradation of IKZF1 and IKZF3 Blood ·Jan Krönke, Namrata D. Udeshi, Anupama Narla, Peter Grauman, Slater N. Hurst, Marie McConkey, Tanya Svinkina, Dirk Heckl, Eamon Comer, Xiaoyu Li, Christie Ciarlo, Emily C. Hartman, Monica Schenone, Stuart L. Schreiber, Steven A. Carr, Benjamin L. Ebert	2013	1
13	SETD2 Heterozygous Loss in Leukemia Leads to Chemotherapy Resistance through Attenuation of the DNA Damage Response Blood ·Brenton G. Mar, Josephine Kahn, Rebecca L. Zon, Peter Grauman, Kevin Boettger, S. Haihua Chu, Scott A. Armstrong, Benjamin L. Ebert	2015	0

About Peter Grauman

Peter Grauman is a scholar working on Hematology, Molecular Biology, Genetics, Pediatrics, Perinatology and Child Health and Public Health, Environmental and Occupational Health, having authored 13 papers that have together received 2.7k indexed citations. Recurring topics across this work include Acute Myeloid Leukemia Research (5 papers), Epigenetics and DNA Methylation (4 papers), Genomics and Rare Diseases (4 papers), Protein Degradation and Inhibitors (3 papers), Acute Lymphoblastic Leukemia research (3 papers), Multiple Myeloma Research and Treatments (3 papers), Cancer Genomics and Diagnostics (2 papers) and Prenatal Screening and Diagnostics (2 papers). The work is most often cited by research in Hematology (1.6k citations), Genetics (511 citations), Molecular Biology (1.7k citations), Oncology (555 citations) and Cancer Research (255 citations). Peter Grauman has collaborated with scholars based in United States, Germany and Netherlands. Frequent co-authors include Benjamin L. Ebert, Marie McConkey, Christie Ciarlo, Nikhil C. Munshi, Emily C. Hartman, Xiaoyu Li, Monica Schenone, Stuart L. Schreiber, Jan Krönke and Eamon Comer. Their work appears in journals such as Blood, Clinical Chemistry, Science, Nature Communications and New England Journal of Medicine.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact